Feature | March 23, 2015

JACC Reports on First-In-Human Transcatheter Tricuspid Repair

Mitralign transcatheter annuloplasty system could present non-surgical option for both mitral and tricuspid valve regurgitation

Mitralign, transcatheter triscupid repair, TTVR, TR, first in human

March 23, 2015 — A detailed reporting of the first successful case of a direct transcatheter tricuspid repair (TTVR) for severe TR has been reported by Prof. J. Schofer, M.D., of the Medicare Center and Department for Percutaneous Interventions of Structural Heart Disease, Albertinen Heart Center, Hamburg. Schofer’s report appears in the current issue of the peer-reviewed Journal of the American College of Cardiology (JACC). The Mitralign System is currently being evaluated in clinical trials for an indication in functional mitral regurgitation. The device is not approved for sale or distribution in the EU or United States.

“We are pleased to see the development of the Mitralign System to not only treat mitral regurgitation but to potentially be the non-surgical option for patients suffering from tricuspid regurgitation,” said Schofer. “These are challenging disease states. Surgery for tricuspid regurgitation suffers from high mortality rates and for those who do undergo surgery, reoccurrence is high as well. A transcatheter option is needed for this underserved patient population.”

The patient was an 89-year-old woman who was suffering from mild to moderate mitral and aortic regurgitation and severe tricuspid regurgitation. She underwent a transcatheter bicuspidization of the tricuspid valve, successfully converting a regurgitating tri-leaflet valve into a functioning bi-leaflet valve. The patient was discharged five days later.

In an accompanying editorial, William W. O’Neill, M.D., and Brian P. O’Neill, M.D. noted that “Tricuspid regurgitation (TR) remains an undertreated problem with substantial morbidity” and that for “those patients who undergo surgery, recurrence of moderate or severe TR can be as high as 60 percent at five years”. The editorial also notes that despite a one-year mortality rate of 36.1 percent for patients with severe TR, only 16 percent of patients with isolated severe TR underwent surgery at five years.

“This is the first experience with a transcatheter tricuspid annuloplasty device, and we were able to immediately quantify dimensional changes and see significant reduction in tricuspid regurgitation” stated Rebecca Hahn, M.D. “Imaging with 2-D and 3-D echocardiography is feasible and essential for the advancement of this technology.”

For more information: www.mitralign.com


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
Subscribe Now